Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer
作者:Andreas Luxenburger、Nicola Bougen-Zhukov、Michael G. Fraser、Henry Beetham、Lawrence D. Harris、Dorian Schmidt、Scott A. Cameron、Parry J. Guilford、Gary B. Evans
DOI:10.1021/acs.jmedchem.1c01609
日期:2021.12.23
optimize 1. Overall, 63 analogues were synthesized and tested for their SL activity toward isogenic mammary epithelial CDH1-deficient cells (MCF10A-CDH1–/–). Among the 26 compounds with greater cytotoxicity, AL-GDa62 (3) was four-times more potent and more selective than 1 with an EC50 ratio of 1.6. Furthermore, 3 preferentially induced apoptosis in CDH1–/– cells, and Cdh1–/– mammary and gastric organoids
弥漫性胃癌和小叶乳腺癌是侵袭性恶性肿瘤,通常与肿瘤抑制基因CDH1 的失活突变有关。由CDH1功能障碍引起的合成致死 (SL) 漏洞代表了药物开发的有吸引力的目标。最近,SLEC-11 ( 1 ) 作为 E-钙粘蛋白缺陷细胞中的 SL 前导出现。在这里,我们描述了我们为优化1所做的努力。总体而言,合成了 63 种类似物并测试了它们对同基因乳腺上皮CDH1缺陷细胞 (MCF10A- CDH1 –/– ) 的 SL 活性。在 26 种细胞毒性较大的化合物中,AL-GDa62 ( 3) 的效力和选择性是1的四倍,EC 50比率为 1.6。此外,3优先诱导CDH1 –/–细胞凋亡,并且Cdh1 –/–乳腺和胃类器官在低微摩尔浓度下对3明显更敏感。处理过的 MCF10A -CDH1 –/–细胞蛋白裂解物的热蛋白质组分析显示,3特异性抑制 TCOF1、ARPC5 和 UBC9。在体外,3在低微摩尔浓度下抑制